Conference report: International Conference on HIV and iron, Brugge 1997

Tropical Medicine and International Health

Volumn 2, Issue 11, 1997, Pages 1102-1106

  Boelaert, Johan R ^a   Gordeuk, Victor R ^b   Piette, Jacques ^c   Weinberg, Geoffrey A ^d  

^a General Hospital St Jan   (Belgium)

^b GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF LIÈGE   (Belgium)

^d UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BELGIUM; CONFERENCE PAPER; GENE ACTIVATION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IRON METABOLISM; PATHOGENESIS;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0030678033     PISSN: 13602276     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3156.1997.d01-177.x     Document Type: Conference Paper

References (29)

1. Boelaert JR, Weinberg GA & Weinberg KD (1996a) Altered iron metabolism in HIV infection: mechanisms, possible consequences, and proposals for management. Infectious Agents and Disease 5, 36-46.
2. Boelaert JR, Piette J, Weinberg GA, Sappey C & Weinberg ED (1996b) Iron and oxidative stress as a mechanism for the enhanced production of human immunodeficiency virus by alveolar macrophages from otherwise healthy cigarette smokers. Journal of Infectious Diseases 173, 1045-1046.
3. Brittenham GM (1992) Development of iron chelating agents for clinical use. Blood 80, 569-572.
4. Brock JH (1994) Iron in infection, immunity, inflammation and neoplasia. In Iron metabolism in health and disease (eds. JH Brock, JW Halliday, MJ Pippard & LW Powell) Saunders, London, pp. 353-390.
5. Costagliola DG, de Montalembert M, Lefrère JJ et al. (1994) Dose of desferrioxamine and evolution of HIV-I infection in thalassaemic patients. British Journal of Haematology 87, 849-852.
6. De Sousa M, Reimao R, Lacerda R, Hugo P, Kaufman SHE & Porto G (1994) Iron overload in β2-microglobulin-deficient mice. Immunology Letters 39, 105-111.
7. Eck H-P, Gmunder H, Hartmann M, Petzoldt D, Daniel V & Dröge W (1989) Low concentrations of acid-solvable thiol (cysteine) in the blood of HIV-I infected patients. Biology and Chemistry Hoppe-Seyler 370, 101-107.
8. Feder JN, Grirke A, Thomas W et al. (1996) A novel MCH class I-like gene is mutated in patients with hereditary haemochromatosis. Nature Genetics 13, 399-408.
9. Gordeuk VR, McLaren G & Samowitz W (1994) Etiologies, consequences and treatment of iron overload. Critical Review of Laboratory Clinical Medicine 31, 89-133.
10. Gougeon ML & Montagnier L (1993) Apoptosis in AIDS. Science 260, 1269-1274.
11. Herzenberg L, De Rosa SC, Dubs JG et al. (1997) Glutathione deficiency is associated with impaired survival in HIV disease. Proceedings of the National Academy of Sciences of the United States of America 94, 1962-1967.
12. Hider RC, Choudhury R, Rai BL, Dekhordi LS & Singh S (1996) Design of orally active iron chelators. Acta Haematologica 95, 6-12.
13. Jacobus DP (1996) Randomization to iron supplementation of patients with advanced human immunodeficiency virus disease and inadvertent but controlled study with results important for patient care. Journal of Infectious Diseases 172, 1044-1045.
14. Langlois MR & Delanghe JR (1996) Biological and clinical significance of haptoglobin polymorphism in humans. Clinical Chemistry 42, 1589-1600.
15. Legrand-Poels S, Vaira D, Van Pincemail J, de Vorst A & Piette J (1990) Activation of human immunodeficiency virus type I by oxidative stress. AIDS Research and Human Retroviruses 6, 1389-1397.
16. Mazzolla R, Barluzzi R, Brozzetti A et al. (1997) Enhanced resistance to Cryptococcus neoformans infection induced by chloroquine in a murine model of meningoencephalitis. Antimicrobial Agents and Chemotherapy 41, 802-807.
17. Mencacci A, Cenci E, Boelaert JR et al. (1997) Iron overload alters T-helper cell responses to Candida albicans in mice. Journal of Infectious Diseases 175, 1467-1476.
18. Merali S, Chin K, Grady RW & Clarkson AB Jr (1996) Trophozoite elimination in a rat model of Pneumocystis carinii pneumonia by clinically achievable plasma deferoxamine concentrations. Antimicrobial Agents and Chemotherapy 40, 1298-1300.
19. Pantaleo G (1997) How immune-based interventions can change HIV therapy. Nature Medicine 3, 483-486.
20. Salmon-Ceron D, Fontbonne A, Saba J et al. (1995) Lower survival in AIDS patients receiving dapsone compared with aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia. Journal of Infectious Diseases 172, 656-664.
21. Sappey C, Boelaert JR, Legrand-Poels S, Forceille C., Favier A & Piette J (1995) Iron chelation decreases NF-kB and HIV type I activation due to oxidative stress. AIDS Research and Human Retroviruses 11, 1049-1059.
22. Shatrov VA, Boelaert JR, Dröge W & Lehman V (1997) Iron chelation decreases HIV-I tat potentiated TNF-induced NF-kB activation in Jurkat cells. European Cytokine Network 8, 37-43.
23. Soteriadou K, Papavassiliou P, Voyiatzaki C & Boelaert JR (1995) Effect of iron chelation on the in-vitro growth of Leishmania promastigotes. Antimicrobials and Chemotherapy 35, 23-19.
24. Sperber K, Louie M, Kraus T et al. (1995) Hydroxychloroquine treatment of patients with human immunodeficiency virus type I. Clinical Therapeutics 17, 622-636.
25. Weinberg GA (1994) Iron chelators as therapeutic agents against Pneumocystis carinii. Antimicrobial Agents and Chemotherapy 38, 997-1003.
26. Weinberg ED & Weinberg GA (1995) The role of iron in infection. Current Opinion in Infectious Disease 8, 164-169.
27. Weiss G, Thuma PE, Mabeza G, Werner ER, Herold M & Gordeuk VR (1997) Modulatory potential of iron chelation therapy on nitric oxide formation in cerebral malaria. Journal of Infectious Diseases 175, 226-230.
28. Weiss G, Wachter H & Fuchs D (1995) Linkage of cell-mediated immunity to iron metabolism. Immunology Today 16, 495-500.
29. Ziegler J (1993) Endemic Kaposi sarcoma in Africa and local volcanic soils. Lancet 342, 1348-1351.